Pharmacological Impacts of Serotonin Reuptake Inhibitors on Hemostasis

Serotonin reuptake inhibitors, particularly selective agents (SSRIs), are widely employed in the management of mood disorders and are increasingly recognised for their effects on blood clotting processes. By blocking the serotonin transporter on platelets, these drugs reduce intraplatelet serotonin levels and attenuate platelet aggregation responses. Clinically, this mechanism manifests as an elevated tendency to bleed, with implications for surgical risk, gastrointestinal haemorrhage and interactions with anticoagulant or antiplatelet regimens. The pharmacological modulation of platelet function by SSRIs encompasses altered intracellular calcium signalling, reduced granule secretion and diminished expression of adhesion molecules. These changes may translate to both reduced arterial thrombosis risk and increased bleeding complications, demanding careful consideration when co‐prescribing SSRIs with other haemostatic agents. Global relevance emerges from the high prevalence of SSRI use in diverse populations and the universal need to balance antidepressant efficacy against safety in haemostasis. Practical applications include the refinement of perioperative guidelines, the development of predictive tools for adverse events and personalised therapy adjustments based on bleeding risk profiles.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Impacts of Serotonin Reuptake Inhibitors on Hemostasis publication trend

The graph below shows the total number of articles in pharmacological impacts of serotonin reuptake inhibitors on hemostasis across all publications each year (not limited to Nature Index journals).

Technical terms

Hemostasis: The physiological process that stops bleeding by clot formation and vessel repair.

Selective serotonin reuptake inhibitor (SSRI): A class of antidepressant drugs that block the serotonin transporter to increase extracellular serotonin levels.

Platelet aggregation: The clumping together of platelets in blood, a critical step in clot formation.

Antithrombotic therapy: Medical treatment, including anticoagulants and antiplatelet agents, designed to prevent clot formation.

References

1. Using machine learning to develop a clinical prediction model for SSRI-associated bleeding: a feasibility study. BMC Medical Informatics and Decision Making (2023).
2. Serotonin‐Affecting Antidepressant Use in Relation to Platelet Reactivity. Clinical Pharmacology & Therapeutics (2022).
3. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Annals of Medicine (2021).